ROCKVILLE, Md., Feb. 01, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support innovative cell-based research, today announced that it will release financial results for the fourth quarter and full year 2022 after the U.S. market close on Wednesday, March 15 th , 2023. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.
Earnings Conference Call Details
Investors interested in listening to the conference call are required to register online . It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the “Events” section of the MaxCyte website at https://investors.maxcyte.com/ .
Company management will also participate in the following investor conferences:
- BIO CEO & Investor Conference
Tuesday, February 7 th at 3:15 p.m. Eastern Time
- BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Tuesday, February 14 th
- 43 rd Annual Cowen Healthcare Conference
Tuesday, March 7 th at 11:10 a.m. Eastern Time
A live and archived webcast of the Cowen presentation will be available on the “Events” section of the MaxCyte investor relations website at https://investors.maxcyte.com/ .
About MaxCyte
MaxCyte is a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support innovative, cell-based research. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™ GTx™ and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.
MaxCyte Contacts:
US IR Adviser
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500
UK IR Adviser
Consilium Strategic Communications
Mary-Jane Elliott / Chris Welsh
+44 (0)203 709 5700
maxcyte@consilium-comms.com